蒿属花粉特异性免疫治疗变应性鼻炎的临床疗效观察

刘艾竹; 王学艳; 尹金淑; 于睿莉; 马婷婷

doi:10.13201/j.issn.1001-1781.2018.20.011

蒿属花粉特异性免疫治疗变应性鼻炎的临床疗效观察

- 1. 首都医科大学附属北京世纪坛医院耳鼻咽喉头颈外科(北京, 100038);
- 2. 首都医科大学附属北京世纪坛医院变态反应科

详细信息

通讯作者: 王学艳, E-mail:btfywangxueyan@126.com

中图分类号: R765.21

收稿日期: 2018-06-07

Clinical observation on specific immunotherapy of allergic rhinitis with artemisia pollen

- 1. Department of Otolaryngology Head and Neck Surgery,Beijing Shijitan Hospital Affiliated Captital Medical Hospital, Beijing,100038,China;
- 2. Allergic Consulting Department,Beijing Shijitan Hospital Affiliated Captital Medical Hospital

More Information

Corresponding author: WANG Xueyan, E-mail: btfywangxueyan@126.com

Received Date: 07 June 2018

摘要

摘要:
目的: 观察蒿属花粉特异性免疫治疗变应性鼻炎的临床疗效。方法: 选取变应原皮肤点刺试验蒿属花粉为阳性的变应性鼻炎患者139例,均行蒿属花粉特异性免疫治疗,间隔3个月复诊,分别于治疗前(N)、治疗开始后间隔3个月(D1,D2,D3)随访填写鼻症状总积分表(TNSS)、视觉模拟量表(VAS)评分、嗅觉功能分级、眼部症状评分(TOSS)及鼻结膜炎生活质量问卷(RQLQ)评分。结果: TNSS评分:N>D1,N>D2,N>D3,D1、D2、D3两两相比无差异;VAS评分:N>D1,N>D2,N>D3,D1、D2、D3两两相比无差异;嗅觉功能分级:N>D1,N>D2,N>D3,D1、D2、D3两两相比无差异;TOSS评分:N>D1,N>D2,N>D3,D1、D2、D3两两相比,其中D1>D2,其余无差异;RQLQ评分:N>D1,N>D2,N>D3,D1>D2,D3>D1,D3>D2。结论: 蒿属花粉特异性免疫治疗对变应性鼻炎疗效确切,症状改善明显。
- 鼻炎 /
- 变应性 /
- 花粉症 /
- 特异性免疫治疗 /
- 治疗结果
Abstract: Objective: The aim of this study is to observe the clinical efficacy of pollen specific immunotherapy with Artemisia in allergic rhinitis.Method: A total of 139 patients with allergic rhinitis who were positive for Artemisia pollen were selected for allergen skin pricking. All of them were treated with Artemisia pollen-specific immunotherapy. The patients were followed up for 3 months, respectively before treatment (N), after treatment start interval. 3 months (D1, D2, D3) follow-up fill in the total score of nasal symptoms (TNSS), visual analogue scale (VAS) score, olfactory function grading, ocular symptom score (TOSS) and rhinoconjunctivitis quality of life questionnaire (RQLQ))score.Result: TNSS:N>D1,N>D2,N>D3,D1,D2,D3 two of the three compared to no difference.VAS:N>D1,N>D2,N>D3,among D1,D2,D3, two of the three compared to no difference. Olfactory function classification:N>D1,N>D2,N>D3,among D1,D2,D3, two of the three compared to no difference.TOSS:N>D1,N>D2,N>D3,among D1,D2,D3,D1>D2,the rest had no difference. RQLQ:N>D1, N>D2, N>D3, D1>D2, D3>D1, D3>D2.Conclusion: The specific pollen immunotherapy of artemisia is effective in the treatment of allergic rhinitis, and the symptoms are obviously improved.
- rhinitis /
- allergic /
- pollinosis /
- specific immunotherapy /
- treatment outcome

HTML全文

参考文献(20)

[1]	海英, 白彩明, 裴潇竹, 等.哈尔滨地区蒿属花粉过敏临床流行病学调查[J].现代生物医学进展, 2012, 12 (30):5871-5873.
[2]	EMBERLIN J.Asthma and rhinitis[M]//BUSSE W, HOLGATE S.Aero biology.2nd.Oxford:Blackwell Science, 2000:1083-1107.
[3]	谢立锋, 朱丽, 张丰珍, 等.风媒花木本植物盛花期与变应性鼻炎就诊率的关系分析[J].临床耳鼻咽喉头颈外科杂志, 2016, 30 (15):1206-1209.
[4]	王春, 于博, 孔慧, 等.变异性鼻炎致病环境因素的研究[J].医学与哲学, 2013, 34 (4):67-71.
[5]	马婷婷, 王学艳, 潘磊.过敏性哮喘合并鼻炎患者危险因素的Lodistic回归分析[J].医学与哲学, 2017, 38 (1B):53-56.
[6]	郭杰峰, 刘萍, 伍慧卿, 等.特异性免疫治疗对变应性鼻炎患者心理和生活质量影响的研究[J].临床耳鼻咽喉头颈外科杂志, 2016, 30 (9):712-714.
[7]	叶世泰, 张金谈, 顾瑞金, 等.中国气传致敏花粉调查[M].北京:北京出版社, 1991:44-148.
[8]	姚丽娜, 张宏誉.北京市气传蒿属花粉浓度调查[J].临床耳鼻咽喉头颈外科杂志, 2009, 23 (20):913-916.
[9]	高星星, 张续德.潍坊市夏秋季气传花粉的调查[J].免疫学杂志, 2015, 38 (8):733-736.
[10]	乔秉善.中国气传花粉和植物[M].北京:中国协和医科大学出版社, 2004:228-238.
[11]	孟娟, 张虹婷, 刘锋, 等.视觉模拟评分法与分级评分法在变应性鼻炎患者症状评估中的应用[J].中国中西医结合耳鼻咽喉科杂志, 2015, 23 (5):330-334.
[12]	BOUSQUEL J, KHALTAEV N, CRUZ A A, et al.Allergic Rhinitis andits Impact on Asthma (ARIA) 2008updat[J].Allergy, 2008, 63 Suppl 86:8-160.
[13]	陈建军, 孔维佳, 项济生, 等.变应性鼻炎伴哮喘患者特异性免疫治疗的疗效分析[J].临床耳鼻咽喉头颈外科杂志, 2010, 24 (2):57-59.
[14]	王丰, 张虹婷, 孟娟.皮下免疫与舌下免疫治疗变应性鼻炎的疗效比较[J].重庆医学, 2017, 46 (21):2906-2908.
[15]	AKDIS M.Immune tolerance in allergy[J].Curr Opin Immunol, 2009, 21:700-707.
[16]	裴莹莹, 徐博怀, 胡德强, 等.变应性鼻炎皮下特异性免疫治疗研究进展[J].新医学, 2017, 48 (3):148-152.
[17]	AKDIS M, AKDIS C A.Mechanisms of allergen-specific immunotherapy[J].J Allergy Clin Immunol, 2007, 119:780-789.
[18]	KUSSEBI F, KARAM LOO F, AKDIS M, et al.Advances in immunological treatment of allergy[J].Curr Med Chem, 2003, 2:297-308.
[19]	邱前辉.变应性鼻炎免疫治疗的现状和未来[J].临床耳鼻咽喉头颈外科杂志, 2017, 31 (1):9-31.
[20]	EPSTEIN T G, LISS G M, MURPHY-BERENDTSK, et al.AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012:an update on fatal and nonfatal systemic allergic reactions[J].JAllergy Clin Immunol Pract, 2014, 2:161-167.